VRDN (Viridian Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

VRDN (Viridian Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

VRDNViridian Therapeutics, Inc.

Mkt Cap$3B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$71M

Net Income (TTM)-$343M

EPS (TTM)-$3.32

Free Cash Flow (TTM)-$277M

Gross Margin99.5%

Op. Margin-512.9%

Net Margin-483.6%

FCF Margin-390.8%

P/S Ratio (TTM)35.6x

P/E Ratio (TTM)—

YoY Rev Growth+23359.9%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$98K	$98K	-$72M
Q2 23	$72K	$72K	-$59M
Q3 23	$72K	$72K	-$51M
Q4 23	$72K	$72K	-$71M
Q1 24	$72K	$72K	-$56M
Q2 24	$72K	$72K	-$72M
Q3 24	$86K	$86K	-$83M
Q4 24	$72K	$72K	-$87M
Q1 25	$72K	$72K	-$94M
Q2 25	$75K	$75K	-$107M
Q3 25	$71M	$71M	-$40M
Q4 25	$132K	-$188K	-$123M

Valuation

Quarter	P/S	P/E
Q1 23	1526.2x	—
Q2 23	1717.2x	—
Q3 23	7274.5x	—
Q4 23	8039.0x	—
Q1 24	8764.8x	—
Q2 24	8764.8x	—
Q3 24	8358.5x	—
Q4 24	8358.5x	—
Q1 25	8358.5x	—
Q2 25	8276.3x	—
Q3 25	35.7x	—
Q4 25	35.6x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$62M	-$62M
Q2 23	-$45M	-$46M
Q3 23	-$39M	-$39M
Q4 23	-$38M	-$38M
Q1 24	-$45M	-$45M
Q2 24	-$46M	-$46M
Q3 24	-$68M	-$68M
Q4 24	-$73M	-$73M
Q1 25	-$93M	-$93M
Q2 25	-$75M	-$75M
Q3 25	-$85M	-$85M
Q4 25	-$24M	-$24M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$115K
Q2 23	$331K
Q3 23	$404K
Q4 23	$48K
Q1 24	$0
Q2 24	$104K
Q3 24	$293K
Q4 24	$114K
Q1 25	$86K
Q2 25	$42K
Q3 25	$127K
Q4 25	$240K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	-54.6%	+178.0%
Q2 23	-71.9%	+99.0%
Q3 23	-94.0%	+65.6%
Q4 23	-31.4%	+45.5%
Q1 24	-26.5%	-22.9%
Q2 24	+0.0%	+21.8%
Q3 24	+19.4%	+62.9%
Q4 24	+0.0%	+22.4%
Q1 25	+0.0%	+67.8%
Q2 25	+4.2%	+47.9%
Q3 25	+81958.1%	+32.3%
Q4 25	+83.3%	+40.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$15M	15526.5%
Q2 23	$12M	17086.1%
Q3 23	$14M	18897.2%
Q4 23	$26M	36177.8%
Q1 24	$13M	17622.2%
Q2 24	$12M	16343.1%
Q3 24	$9M	10139.5%
Q4 24	$9M	12465.3%
Q1 25	$10M	14194.4%
Q2 25	$11M	14458.7%
Q3 25	$11M	15.9%
Q4 25	$12M	9082.6%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$51M	$22M
Q2 23	$40M	$19M
Q3 23	$30M	$21M
Q4 23	$39M	$33M
Q1 24	$41M	$15M
Q2 24	$56M	$16M
Q3 24	$69M	$14M
Q4 24	$72M	$16M
Q1 25	$77M	$17M
Q2 25	$87M	$20M
Q3 25	$86M	$24M
Q4 25	$89M	$34M

Revenue Segments

Quarter	Collaboration Revenue	Collaboration	License
Q1 23	$100K	—	—
Q3 25	—	$570K	$70M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$89M	$285M	$374M
Q2 23	$87M	$247M	$334M
Q3 23	$112M	$201M	$313M
Q4 23	$103M	$375M	$477M
Q1 24	$92M	$522M	$613M
Q2 24	$108M	$464M	$571M
Q3 24	$200M	$553M	$753M
Q4 24	$100M	$618M	$718M
Q1 25	$116M	$520M	$637M
Q2 25	$117M	$446M	$563M
Q3 25	$170M	$321M	$491M
Q4 25	$212M	$662M	$875M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	42M	+4.2%
Q2 23	43M	+2.4%
Q3 23	44M	+0.9%
Q4 23	50M	+13.8%
Q1 24	61M	+23.0%
Q2 24	64M	+4.5%
Q3 24	66M	+4.0%
Q4 24	80M	+20.5%
Q1 25	81M	+1.6%
Q2 25	82M	+0.3%
Q3 25	82M	+0.2%
Q4 25	85M	+3.7%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$154K	28
FY 15	$79K	32
FY 16	$74K	45
FY 17	$62K	65
FY 18	$105K	80
FY 19	$97K	46
FY 20	$39K	27
FY 21	$59K	50
FY 22	$21K	86
FY 23	$3K	94
FY 24	$2K	143
FY 25	$281K	252